7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,442.06

+240.54

+0.31%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqCM - Nasdaq Real Time Price USD

Aclarion, Inc. (ACON)

1.9500 -0.0200 (-1.02%)

At close: October 30 at 4:00:01 PM EDT

1.9314 -0.0186 (-0.95%)

After hours: October 30 at 6:29:19 PM EDT

Loading Chart for ACON

Chart Range Bar

Interval:

In partnership with ChartIQ

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Aclarion to Present at the 20th Annual LD Micro Main Event

Aclarion to Present at the 20th Annual LD Micro Main Event

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Mobilize your Website

View Site in Mobile | Classic

Share by: